Abstract library

67 results for "interval".
#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Ivana Puliafito
#1798 Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients wth Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Marianne Pavel
Authors: Pavel M, Dromain C, Majdi A, Houchard A, ...
#1372 The Role of Interval CT Scanning in Patients Undergoing Palliative Chemotherapy for Metastatic Neuroendocrine Tumours (NETs)
Introduction: In NET, radiological response to chemotherapy is often delayed and the importance of interval-imaging during treatment has not been determined.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Rowan Miller
Authors: Miller R, Childs A, Gillmore R, Mayer A, ...
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy
Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
Keywords: PRRT
#1326 Clinical Nurse Specialist in NET Patients at Institut Català d’ Oncologia - ICO
Introduction: A Functional Unit model brings together multidisciplinary professionals participating in a committee. Its aim is to optimize diagnostic and therapeutic intervals, get consensus on the best-individual treatment option & best evidence. Our unit-NET, was establish 10 years ago & last 4 got a clinical nurse specialist-CNS
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: RN, PhDcandidate Paz Fernandez
Keywords: Clinical nurse
#1397 The Relation Between GEP-NEN Prognosis Re-Stratification and Ki-67 Variability: From a Single Institution Study
Introduction: Ki-67 has been identified as a prognostic factor for GEP NEN.The variability of Ki-67 during the disease course has been reported,but there's few about its effects on prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Zhang Qin
Authors: Rong L, Qin Z, ...
#1491 Do Medical Oncology Services Receive More Patients with Neuroendocrine Tumors? Assessment of This Tendency and Reflections About Its Aid Complexity
Introduction: Neuroendocrine tumors meant a change in the clinical practice, multidisciplinary approach (MA) is the gold standard today.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Carmen Salvador
#1552 Liver Transplantation for Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NET) are rare neoplasms and liver transplantation (LT) for hepatic metastases is indicated in selected cases where other therapies have failed.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: PhD Estela Regina Ramos Figueira
#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran